Maiwald Intellectual Property

Susanna Heurung of Maiwald welcomes a decision by the Board of Appeal regarding the extension of a grace period for use where the applicant’s bad faith was obvious

In concluding a two-part series on springboard injunctions, Marco Stief of Maiwald takes a deeper dive to explain their requirements, review case law, and examine their relevance in the pharmaceutical and life sciences sectors

In the first of two articles on the springboard doctrine, Marco Stief of Maiwald explains how the protective effect of a patent can continue to have an impact after the term of protection has ended

Gisela Grabow of Maiwald considers the potential changes to the EU’s general pharmaceutical legislation under a recent proposal, and the main questions raised for stakeholders

Christian Meyer of Maiwald explains several clarifications under a ruling by the German Federal Court of Justice concerning the cessation of the danger of a repeated infringement

Bo-Hyun Lee of Maiwald considers how the Unified Patent Court will affect the successful German model of having patent attorneys and attorneys-at-law work together to handle the technical aspects of infringement proceedings